Your browser doesn't support javascript.
loading
The effects of selected sedatives on basal and stimulated serum cortisol concentrations in healthy dogs.
Hunt, Adam; Olin, Shelly; Whittemore, Jacqueline C; Esteller-Vico, Alejandro; Springer, Cary; Giori, Luca.
Affiliation
  • Hunt A; Department of Small Animal Clinical Sciences, University of Tennessee, College of Veterinary Medicine, Knoxville, TN, United States of America.
  • Olin S; Department of Small Animal Clinical Sciences, University of Tennessee, College of Veterinary Medicine, Knoxville, TN, United States of America.
  • Whittemore JC; Animal Emergency and Specialty Center, Knoxville, TN, United States of America.
  • Esteller-Vico A; University of Tennessee, College of Veterinary Medicine, Department of Biomedical and Diagnostic Sciences, TN, United States of America.
  • Springer C; Research Computing Support, Office of Information Technology, University of Tennessee-Knoxville, Knoxville, TN, United States of America.
  • Giori L; University of Tennessee, College of Veterinary Medicine, Department of Biomedical and Diagnostic Sciences, TN, United States of America.
PeerJ ; 12: e16955, 2024.
Article in En | MEDLINE | ID: mdl-38406286
ABSTRACT

Background:

Hormone assessment is typically recommended for awake, unsedated dogs. However, one of the most commonly asked questions from veterinary practitioners to the endocrinology laboratory is how sedation impacts cortisol concentrations and the adrenocorticotropic hormone (ACTH) stimulation test. Butorphanol, dexmedetomidine, and trazodone are common sedatives for dogs, but their impact on the hypothalamic-pituitary-adrenal axis (HPA) is unknown. The objective of this study was to evaluate the effects of butorphanol, dexmedetomidine, and trazodone on serum cortisol concentrations.

Methods:

Twelve healthy beagles were included in a prospective, randomized, four-period crossover design study with a 7-day washout. ACTH stimulation test results were determined after saline (0.5 mL IV), butorphanol (0.3 mg/kg IV), dexmedetomidine (4 µg/kg IV), and trazodone (3-5 mg/kg PO) administration.

Results:

Compared to saline, butorphanol increased basal (median 11.75 µg/dL (range 2.50-23.00) (324.13 nmol/L; range 68.97-634.48) vs 1.27 µg/dL (0.74-2.10) (35.03 nmol/L; 20.41-57.93); P < 0.0001) and post-ACTH cortisol concentrations (17.05 µg/dL (12.40-26.00) (470.34 nmol/L; 342.07-717.24) vs 13.75 µg/dL (10.00-18.90) (379.31 nmol/L; 275.96-521.38); P ≤ 0.0001). Dexmedetomidine and trazodone did not significantly affect basal (1.55 µg/dL (range 0.75-1.55) (42.76 nmol/L; 20.69-42.76); P = 0.33 and 0.79 µg/dL (range 0.69-1.89) (21.79 nmol/L; 19.03-52.14); P = 0.13, respectively, vs saline 1.27 (0.74-2.10) (35.03 nmol/L; 20.41-57.93)) or post-ACTH cortisol concentrations (14.35 µg/dL (range 10.70-18.00) (395.86 nmol/L; 295.17-496.55); (P = 0.98 and 12.90 µg/dL (range 8.94-17.40) (355.86 nmol/L; 246.62-480); P = 0.65), respectively, vs saline 13.75 µg/dL (10.00-18.60) (379.31 nmol/L; 275.86-513.10).

Conclusion:

Butorphanol administration should be avoided prior to ACTH stimulation testing in dogs. Further evaluation of dexmedetomidine and trazodone's effects on adrenocortical hormone testing in dogs suspected of HPA derangements is warranted to confirm they do not impact clinical diagnosis.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Deep Sedation / Hypnotics and Sedatives Limits: Animals Language: En Journal: PeerJ Year: 2024 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Deep Sedation / Hypnotics and Sedatives Limits: Animals Language: En Journal: PeerJ Year: 2024 Document type: Article Affiliation country: United States